1,2,4,-trioxepanes as precursors for lactones

Details for Australian Patent Application No. 2004263256 (hide)

Owner Akzo Nobel N.V.

Inventors Meijer, John; Van Den Berg, Rolf Hendrik

Agent Griffith Hack

Pub. Number AU-A-2004263256

PCT Pub. Number WO2005/014569

Priority 60/499,415 02.09.03 US; 03077238.8 17.07.03 EP

Filing date 12 July 2004

Wipo publication date 17 February 2005

International Classifications

C07D 313/00 (2006.01) Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom

C07D 315/00 (2006.01) Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups

C07D 321/00 (2006.01) Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups

C07D 323/00 (2006.01) Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms

Event Publications

9 March 2006 PCT application entered the National Phase

  PCT publication WO2005/014569 Priority application(s): WO2005/014569

10 July 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004263258-Anaqueous solution of a sodium salt of HEDTA

2004263254-Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes